ad_1]
PHILADELPHIA, Aug. 11, 2022 /PRNewswire/ — WuXi Superior Therapies (WuXi ATU), a completely owned subsidiary of WuXi AppTec, immediately introduced a licensing settlement with Janssen Biotech, Inc., one of many Janssen Pharmaceutical Firms of Johnson & Johnson (“Janssen”). Below this settlement, WuXi ATU will license to Janssen its TESSA™ expertise, a high-performance system that may produce 10 occasions extra adeno-associated viral (AAV) vectors than conventional AAV manufacturing techniques. Janssen may also have entry to work on WuXi ATU’s proprietary clonal suspension HEK293 cell line. This settlement was facilitated by Johnson & Johnson Innovation.
AAV vectors are generally used for the supply of gene therapies to sufferers resulting from their potential to transduce quite a few cell and tissue sorts. WuXi ATU’s TESSA™ expertise responds to trade demand for giant scale AAV manufacturing by producing increased high quality AAV particles extra effectively. WuXi ATU has additionally efficiently scaled up the TESSA™ expertise to 200L; this achieved a 10-fold increased yield and a considerably increased proportion of full AAV capsids, drastically decreasing total AAV manufacturing prices in comparison with conventional plasmid-based AAV manufacturing techniques.
“We’re honored that Janssen chosen WuXi ATU’s TESSA™ expertise.” stated Dr. David Chang, Chief Govt Officer of WuXi Superior Therapies. “We stay dedicated to enhancing the TESSA™ platform to provide quicker and cheaper AAV merchandise for sufferers.”
As a Contract Testing, Growth and Manufacturing Group (CTDMO) with world operations, WuXi ATU will proceed to boost its functionality and capability to assist prospects develop and ship life-changing cell and gene therapies quicker for sufferers in want.
About WuXi Superior Therapies (WuXi ATU)
Because the superior therapies enterprise unit of WuXi AppTec, WuXi Superior Therapies is a Contract Testing, Growth and Manufacturing Group (CTDMO) that provides built-in platforms to remodel the invention, growth, testing, manufacturing, and commercialization of cell and gene therapies. Our companies and options speed up time to market and help buyer applications world wide. For extra info, please go to https://www.advancedtherapies.com
About WuXi AppTec
As a world firm with operations throughout Asia, Europe, and North America, WuXi AppTec gives a broad portfolio of R&D and manufacturing companies that allow world pharmaceutical and healthcare trade to advance discoveries and ship groundbreaking therapies to sufferers. Via its distinctive enterprise fashions, WuXi AppTec’s built-in, end-to-end companies embrace chemistry drug CRDMO (Contract Analysis, Growth and Manufacturing Group), biology discovery, preclinical testing and scientific analysis companies, cell and gene therapies CTDMO (Contract Testing, Growth and Manufacturing Group), serving to prospects enhance the productiveness of advancing healthcare merchandise by way of cost-effective and environment friendly options. WuXi AppTec acquired AA ESG ranking from MSCI in 2021 and its open-access platform is enabling greater than 5,850 collaborators from over 30 international locations to enhance the well being of these in want – and to understand the imaginative and prescient that “each drug will be made and each illness will be handled.” Please go to: http://www.wuxiapptec.com
SOURCE WuXi AppTec
